Fagan Associates’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $270K | Hold |
4,452
| – | – | 0.04% | 119 |
|
|
2025
Q4 | $240K | Sell |
4,452
-66,048
| -94% | -$3.18M | 0.03% | 123 |
|
|
2025
Q3 | $3.18M | Sell |
70,500
-6,759
| -9% | -$316K | 0.44% | 60 |
|
|
2025
Q2 | $3.58M | Buy |
77,259
+24,737
| +47% | +$1.21M | 0.55% | 51 |
|
|
2025
Q1 | $3.2M | Buy |
52,522
+46,295
| +743% | +$2.7M | 0.53% | 56 |
|
|
2024
Q4 | $352K | Buy |
6,227
+500
| +9% | +$27.9K | 0.06% | 109 |
|
|
2024
Q3 | $296K | Buy |
+5,727
| New | +$269K | 0.05% | 114 |
|
|
2024
Q2 | – | Sell |
-4,727
| Closed | -$256K | – | 119 |
|
|
2024
Q1 | $256K | Hold |
4,727
| – | – | 0.05% | 113 |
|
|
2023
Q4 | $243K | Sell |
4,727
-62
| -1% | -$3.25K | 0.05% | 107 |
|
|
2023
Q3 | $278K | Hold |
4,789
| – | – | 0.07% | 97 |
|
|
2023
Q2 | $306K | Sell |
4,789
-75
| -2% | -$5.03K | 0.07% | 96 |
|
|
2023
Q1 | $337K | Hold |
4,864
| – | – | 0.08% | 100 |
|
|
2022
Q4 | $350K | Hold |
4,864
| – | – | 0.09% | 98 |
|
|
2022
Q3 | $346K | Hold |
4,864
| – | – | 0.1% | 95 |
|
|
2022
Q2 | $375K | Hold |
4,864
| – | – | 0.1% | 93 |
|
|
2022
Q1 | $355K | Hold |
4,864
| – | – | 0.07% | 111 |
|
|
2021
Q4 | $303K | Sell |
4,864
-54,555
| -92% | -$3.2M | 0.06% | 114 |
|
|
2021
Q3 | $3.52M | Buy |
59,419
+4,626
| +8% | +$305K | 0.76% | 40 |
|
|
2021
Q2 | $3.66M | Buy |
54,793
+460
| +0.8% | +$30K | 0.78% | 38 |
|
|
2021
Q1 | $3.43M | Buy |
54,333
+10,160
| +23% | +$632K | 0.8% | 40 |
|
|
2020
Q4 | $2.74M | Buy |
44,173
+386
| +0.9% | +$23.7K | 0.69% | 42 |
|
|
2020
Q3 | $2.64M | Buy |
43,787
+600
| +1% | +$36.1K | 0.76% | 37 |
|
|
2020
Q2 | $2.54M | Buy |
43,187
+13,731
| +47% | +$821K | 0.81% | 37 |
|
|
2020
Q1 | $1.64M | Buy |
29,456
+9,341
| +46% | +$571K | 0.65% | 43 |
|
|
2019
Q4 | $1.29M | Buy |
20,115
+12,865
| +177% | +$737K | 0.42% | 58 |
|
|
2019
Q3 | $368K | Buy |
+7,250
| New | +$341K | 0.14% | 91 |
|
|
2019
Q2 | – | Sell |
-4,310
| Closed | -$206K | – | 113 |
|
|
2019
Q1 | $206K | Sell |
4,310
-80
| -2% | -$3.98K | 0.09% | 110 |
|
|
2018
Q4 | $228K | Buy |
4,390
+455
| +12% | +$24.4K | 0.12% | 99 |
|
|
2018
Q3 | $244K | Sell |
3,935
-450
| -10% | -$26.7K | 0.1% | 109 |
|
|
2018
Q2 | $243K | Sell |
4,385
-2,685
| -38% | -$145K | 0.11% | 104 |
|
|
2018
Q1 | $447 | Sell |
7,070
-100
| -1% | -$6.43K | 0.19% | 83 |
|
|
2017
Q4 | $439 | Sell |
7,170
-725
| -9% | -$45.3K | 0.18% | 88 |
|
|
2017
Q3 | $503K | Hold |
7,895
| – | – | 0.25% | 80 |
|
|
2017
Q2 | $440K | Sell |
7,895
-350
| -4% | -$19K | 0.23% | 82 |
|
|
2017
Q1 | $448K | Buy |
8,245
+50
| +0.6% | +$2.74K | 0.25% | 77 |
|
|
2016
Q4 | $479K | Buy |
+8,195
| New | +$448K | 0.28% | 79 |
|
Other funds holding BMY
VCM
VPM
Fagan Associates's BMY Position: Q1 2026 in Review
Fagan Associates held its Bristol-Myers Squibb (BMY) position steady in Q1 2026 at 4,452 shares worth $270K. The position accounts for 0.04% of the portfolio, ranked #119.
Fagan Associates first reported a position in BMY in Q4 2016 and has held it in 36 quarters since. The position peaked at $3.66M in Q2 2021. 2,520 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- Fagan Associates held 4,452 shares of Bristol-Myers Squibb worth $270K as of Q1 2026.
- Fagan Associates left its Bristol-Myers Squibb share count unchanged in Q1 2026.
- Bristol-Myers Squibb made up 0.04% of Fagan Associates's portfolio in Q1 2026, its #119 holding.
- Fagan Associates first reported a position in Bristol-Myers Squibb in Q4 2016 and has held it in 36 quarters since.
- Fagan Associates's Bristol-Myers Squibb position peaked at $3.66M in Q2 2021.
- 2,520 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on Fagan Associates's 13F filing for Q1 2026, filed 4 May 2026.